Nurexone Biologic Inc Stock Price, News & Analysis

NurExone Biologic Inc. (NRXBF) presented promising preclinical data on optic nerve regeneration at the ARVO 2025 conference in Salt Lake City. The study, led by Prof. Ygal Rotenstreich, demonstrated that ExoPTEN successfully restored retinal activity and improved optic nerve structure in rat models with optic nerve compression.

The company is advancing its ExoTherapy™ platform, which includes programs for spinal cord and facial nerve regeneration. Previous preclinical spinal cord studies showed ExoPTEN restored motor function in 75% of animals following complete transection. The company is now proceeding to study the therapy in a glaucoma model, targeting a condition that causes significant economic burden to healthcare systems.

NurExone Biologic (NRXBF) has announced breakthrough findings in facial nerve regeneration using their ExoPTEN therapy, marking their third therapeutic indication alongside spinal cord injury and optic nerve regeneration programs. Preclinical studies demonstrated significant functional recovery in facial nerve injury models, potentially addressing conditions like Bell's palsy and Ramsay Hunt Syndrome.

The research, conducted at the Israel Institute of Technology, validates PTEN downregulation as a strategy for axon regrowth. The therapy could target a market where approximately 30% of patients experience long-term functional impairment. The company's ExoTherapy platform utilizes exosomes for precise, minimally-invasive delivery of treatments to injured tissues.

NurExone is preparing an Investigational New Drug (IND) application for ExoPTEN in acute spinal cord injury. The technology is protected by a U.S. patent owned by the Technion, with worldwide exclusive licensing to NurExone, and has been granted in Japan, Russia, and Israel.

NurExone Biologic (TSXV: NRX) (OTCQB: NRXBF) has appointed Jacob Licht as CEO of Exo-Top Inc., its wholly owned subsidiary, and as Vice President of Corporate Development. Exo-Top will serve as a U.S.-based GMP-compliant exosome manufacturing facility, important for NurExone's global supply chain and commercialization strategy.

Licht brings over 20 years of biotech and specialty pharmaceuticals experience, having led transactions worth $1 billion across mergers, acquisitions, licensing, and asset sales. His previous roles include VP positions at Lantheus Medical Imaging, Bavarian Nordic, and Emergent BioSolutions.

Additionally, NurExone has completed its continuance from Alberta to Ontario, following shareholder approval at its June 3, 2024 meeting.

NurExone Biologic (NRXBF) reported its Q4 and full-year 2024 financial results, highlighting progress in its ExoPTEN therapy development for acute Spinal Cord Injury. The company's net loss widened to US$5.04M in 2024 from US$3.64M in 2023, with Q4 2024 net loss at US$1.55M.

Key developments include advancement of ExoPTEN's regulatory pathway towards IND application, establishment of in-house laboratory facilities, and promising preclinical results for treating optic nerve damage. The company's cash position stood at US$0.70M as of December 31, 2024.

Financial highlights show R&D expenses increased to US$1.87M in 2024 (vs US$1.54M in 2023), while G&A expenses rose to US$3.14M (vs US$2.12M). The company recently closed an April 2025 Offering raising C$2.3M through private placement at C$0.65 per unit, with proceeds intended for working capital, U.S. production facility establishment, and planned uplisting to a major U.S. exchange.

NurExone Biologic has successfully closed a non-brokered private placement, raising C$2.3 million through the issuance of 3,543,238 units at C$0.65 per unit. Each unit includes one common share and one warrant, with warrants exercisable at C$0.85 per share for 36 months.

The company plans to utilize the proceeds for working capital, establishing an ExoTop U.S. production facility, and pursuing an uplisting to a major U.S. exchange, subject to regulatory approval. The securities issued are subject to a four-month and one-day statutory hold period.

NurExone Biologic Inc. (NRXBF) has completed a important preclinical study for its ExoPTEN treatment, marking progress toward IND submission and first-in-human trials. The study demonstrated that ExoPTEN significantly improved both motor function recovery and blood flow at spinal cord injury sites.

The research compared two dosing regimens: a single high dose on surgery day versus a lower dose over five consecutive days. Both groups showed notable improvements in motor function recovery compared to the control group, measured by the modified BBB locomotor rating scale. Histological analysis revealed increased average blood vessel size in treated subjects, indicating enhanced circulation important for tissue healing.

Dr. Tali Kizhner, Director of R&D at NurExone, highlighted that the results support ExoPTEN's potential to enhance natural repair mechanisms following spinal cord injury. The company will continue refining ExoPTEN's therapeutic profile as part of its ongoing preclinical program.

NurExone Biologic has been named to the prestigious 2025 TSX Venture 50™, standing out as the only biotech company among three life sciences firms selected. The company achieved remarkable performance metrics, including 110% share price appreciation and 209% market cap growth.

The TSX Venture 50™ recognition, which evaluates companies based on share price appreciation and market capitalization growth, selected NurExone from 1,605 listed issuers. The company's success is driven by significant progress in developing ExoPTEN, their proprietary exosome therapy for acute spinal cord injuries, and the establishment of their U.S. subsidiary, Exo-Top Inc., which enhances their exosome production capabilities.

The 2025 TSX Venture 50™ companies demonstrated an impressive average share price appreciation of 207%, with 80% of the selected companies operating internationally across Europe, South America, Africa, and beyond.